Therapeutic Area: Oncology

SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection

Dykema AG, et al.
EBio Medicine
May 2022
immuneAccess
Authors and Affiliates
Arbor G Dykema 1, Boyang Zhang 2, Bezawit A Woldemeskel 3, Caroline C Garliss 3, Rufiaat Rashid 1, Timothy Westlake 1, Li Zhang 1, Jiajia Zhang 1, Laurene S Cheung 1, Justina X Caushi 1, Drew M Pardoll 1, Andrea L Cox 4, Hongkai Ji 2, Kellie N Smith 5, Joel N Blankson 6; 1 Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA. 2 Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. 3 Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. 4 Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD, USA; Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. 5 Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA. Electronic address: ksmit228@jhmi.edu. 6 Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. Electronic address: jblanks@jhmi.edu.

ADXS31-142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study

Stein MN, et al.
Oncologist
May 2022
Authors and Affiliates
Mark N Stein 1, Lawrence Fong 2, Ronald Tutrone 3, Anthony Mega 4, Elaine T Lam 5, Megan Parsi 6, Surya Vangala 6, Andres A Gutierrez 6, Naomi B Haas 7; 1 Columbia University Medical Center, New York, NY, USA. 2 University of California, San Francisco, CA, USA. 3 Chesapeake Urology Research Associates, Towson, MD, USA. 4 Lifespan Oncology Clinical Research, Rhode Island Hospital, Providence, RI, USA. 5 University of Colorado Cancer Center, University of Colorado Anschutz Medical Center, Aurora, CO, USA. 6 Advaxis, Monmouth Junction, NJ, USA. 7 Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

Kater AP, et al.
NEJM Evidence
May 2022
Authors and Affiliates
Arnon P. Kater, M.D., Ph.D.,1 Carolyn Owen, M.D.,2 Carol Moreno, M.D.,3 George Follows, B.M.Bch., Ph.D.,4 Talha Munir, M.B.B.S.,5 Mark-David Levin, M.D.,6 Ohad Benjamini, M.D.,7 Ann Janssens, M.D., Ph.D.,8 Anders Osterborg, M.D., Ph.D.,9 Tadeusz Robak, M.D., Ph.D.,10 Martin Simkovic, M.D., Ph.D.,11 Don Stevens, M.D.,12 Sergey Voloshin, M.D., Ph.D.,13 Vladimir Vorobyev, Ph.D.,14 Loic Ysebaert, M.D., Ph.D.,15 Rui Qin, Ph.D.,16 Andrew J. Steele, Ph.D.,17 Natasha Schuier, M.D.,18 Kurt Baeten, Ph.D.,19 Donne Bennett Caces, M.D., Ph.D.,16 and Carsten U. Niemann, M.D., Ph.D.,20 for the GLOW Investigators 1 Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, on behalf of the HOVON CLL Working Group, Amsterdam 2 Tom Baker Cancer Centre, Calgary, Alberta, Canada 3 Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona 4 Addenbrooke’s Hospital, Cambridge, UK 5 St James’s Hospital, Leeds, UK 6 Albert Schweitzer Hospital, Dordrecht, Netherlands 7 Sheba Medical Center, Ramat Gan, Israel 8 Universitaire Ziekenhuizen Leuven, Leuven, Belgium 9 Karolinska University Hospital, Stockholm 10 Medical University of Łodz, Copernicus Memorial Hospital, Łodz, Poland 11 University Hospital Hradec Kralove, Hradec Kralove, Czech Republic 12 Norton Cancer Institute, Louisville, KY 13 Russian Scientific Research Institute of Hematology and Transfusiology, St. Petersburg, Russia 14 S.P. Botkin Moscow City Clinical Hospital, Moscow 15 Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France 16 Janssen Research & Development, Raritan, NJ 17 Janssen Research & Development, San Diego, CA 18 Janssen Research & Development, Dusseldorf, Germany 19 Janssen Research & Development, Beerse, Belgium 20 Rigshospitalet Copenhagen University Hospital, Copenhagen

Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer

Burton KA, et al.
JCO Precision Oncology
May 2022
Authors and Affiliates
Kimberly A Burton 1,2,3,4, Elisabeth Mahen 2,5,6, Eric Quentin Konnick 7, Sibel Blau 2,3, Michael O Dorschner 8,9,10, Arturo B Ramirez 11, Stephen C Schmechel 8, Chaozhong Song 2,5,6, Rahul Parulkar 12, Stephanie Parker 3,4, Francis Mark Senecal 3,4, Colin C Pritchard 7, Brigham H Mecham 13, Christopher Szeto 12, Patricia Spilman 14, Jingchun Zhu 15, Vijayakrishna K Gadi 16,17, Roy Ronen 18, Jackie Stilwell 11, Eric Kaldjian 11, Janusz Dutkowski 18, Stephen Charles Benz 12, Shahrooz Rabizadeh 14, Patrick Soon-Shiong 12,14, C Anthony Blau 2,5,6,19; 1 Department of Medicine, University of Washington, Seattle, WA. 2 Center for Cancer Innovation, University of Washington, Seattle, WA. 3 Northwest Medical Specialties, Puyallup and Tacoma, WA. 4 South Sound CARE Foundation, Seattle, WA. 5 Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA. 6 Department of Medicine/Hematology, University of Washington, Seattle, WA. 7 Department of Laboratory Medicine, University of Washington, Seattle, WA. 8 Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA. 9 Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA. 10 Center for Precision Diagnostics, University of Washington, Seattle, WA. 11 Rarecyte Inc, Seattle, WA. 12 NantHealth, Culver City, CA. 13 Trialomics, Seattle, WA. 14 ImmunityBio Inc, Culver City, CA. 15 Computational Genomics Lab, University of California at Santa Cruz, Santa Cruz, CA. 16 Department of Medicine, University of Illinois, Chicago, IL. 17 Fred Hutchinson Cancer Research Center, Seattle, WA. 18 Data4Cure Inc, La Jolla, CA. 19 All4Cure Inc, Seattle, WA.

Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma.

Lakhotia R, et al.
Blood Advances
April 2022
Authors and Affiliates
Rahul Lakhotia,1 Christopher Melani,1 Kieron Dunleavy,2 Stefania Pittaluga,3 Nakhle Saba,4 Liza Lindenberg,5 Esther Mena,5 Ethan Bergvall,6 Andrea Nicole Lucas,7 Allison Jacob,8 Erik Yusko,8 Seth M. Steinberg,9 Elaine S. Jaffe,3 Adrian Wiestner,10 Wyndham H. Wilson,1, and Mark Roschewski1, 1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD; 2Department of Hematology-Oncology, Georgetown University, Washington, DC; 3Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD; 4Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, LA; 5Molecular Imaging Branch, National Cancer Institute, Bethesda, MD; 6Nuclear Medicine Department, Uniformed Services University of the Health Sciences, Bethesda, MD; 7Department of Nursing, Center for Cancer Research, National Cancer Institute, Bethesda, MD; 8Adaptive Biotechnologies, Seattle, WA; 9Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD; and 10Laboratory of Lymphoid Malignancies, National Heart, Lung and Blood Institute, Bethesda, MD

An instructive role for Interleukin-7 receptor α in the development of human B-cell precursor leukemia

Geron I, et al.
Nature Communications
March 2022
Authors and Affiliates
Ifat Geron #,1,2,3, Angela Maria Savino #,1,2,3, Hila Fishman 1,2,3, Noa Tal 1,2, John Brown 4, Virginia A Turati 4, Chela James 4, Jolanda Sarno 5, Michal Hameiri-Grossman 3, Yu Nee Lee 1,6, Avigail Rein 1,2,3, Hillary Maniriho 1,3, Yehudit Birger 1,2,3, Anna Zemlyansky 3, Inna Muler 2, Kara L Davis 5, Victoria Marcu-Malina 7, Nicole Mattson 8, Oren Parnas 9, Rabea Wagener 10, Ute Fischer 10, João T Barata 11, Catriona H M Jamieson 12, Markus Müschen 8, Chun-Wei Chen 8, Arndt Borkhardt 10, Ilan Richard Kirsch 13, Arnon Nagler 1,14, Tariq Enver 4, Shai Izraeli 15,16,17,18; 1 Felsenstein Medical Research Center and The Molecular Genetics and Biochemistry Department, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel. 2 Institute of Pediatric Research, Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Tel Hashomer, Israel. 3 The Rina Zaizov Pediatric Hematology and Oncology Division Schneider Children's Medical Center of Israel, Petach Tikva, Israel. 4 Department of Cancer Biology, UCL Cancer Institute, UCL, London, UK. 5 Department of Pediatrics, Bass Center for Childhood Cancer and Blood Disorders, Stanford University, Stanford, CA, USA. 6 Pediatric Department and the Immunology Service, Jeffrey Modell Foundation Center, Edmond and Lily Safra Children's Hospital Sheba Medical Center, Tel-Hashomer, Israel. 7 Cytogenetic Unit laboratory of Hematology, Chaim Sheba Medical Center Tel Hashomer, Tel Hashomer, Israel. 8 Department of Systems Biology, City of Hope Comprehensive Cancer Center, Monrovia, CA, USA. 9 The Concern Foundation Laboratories at the Lautenberg Center for immunology and Cancer Research, IMRIC, Hebrew University Faculty of Medicine, Jerusalem, Israel. 10 Department of Pediatric Oncology, Hematology and Clinical Immunology, University Children's Hospital, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany. 11 Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. 12 UC San Diego, Moores Cancer Center, Division of Regenerative Medicine, Department of Medicine and Sanford Stem Cell Clinical Center, Ja Jolla, CA, USA. 13 Adaptive Biotechnologies, Inc., Seattle, WA, USA. 14 Hematology Division BMT and Cord Blood Bank Chaim Sheba Medical Center Tel-Hashomer, Tel-Hashomer, Israel. 15 Felsenstein Medical Research Center and The Molecular Genetics and Biochemistry Department, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel. sizraeli@gmail.com. 16 Institute of Pediatric Research, Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Tel Hashomer, Israel. sizraeli@gmail.com. 17 The Rina Zaizov Pediatric Hematology and Oncology Division Schneider Children's Medical Center of Israel, Petach Tikva, Israel. sizraeli@gmail.com. 18 Department of Systems Biology, City of Hope Comprehensive Cancer Center, Monrovia, CA, USA. sizraeli@gmail.com. # Contributed equally

Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia

Bhattacharya D, et al.
Blood Cancer Journal
March 2022
immuneAccess
Authors and Affiliates
Dipabarna Bhattacharya #,1,2, Antonella Teramo #,3, Vanessa Rebecca Gasparini #,3, Jani Huuhtanen #,1,2,4, Daehong Kim 1,2, Jason Theodoropoulos 1,2,4, Gianluca Schiavoni 5, Gregorio Barilà 3, Cristina Vicenzetto 3, Giulia Calabretto 3, Monica Facco 3, Toru Kawakami 6, Hideyuki Nakazawa 6, Brunangelo Falini 5, Enrico Tiacci 5, Fumihiro Ishida 7, Gianpietro Semenzato 3, Tiina Kelkka 1,2, Renato Zambello 3, Satu Mustjoki 8,9,10; 1 Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. 2 Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland. 3 Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova and Veneto Institute of Molecular Medicine (VIMM), Padova, Italy. 4 Department of Computer Science, Aalto University, Espoo, Finland. 5 Institute of Hematology and Center for Hemato-Oncology Research, University and Hospital of Perugia, Perugia, Italy. 6 Department of Internal Medicine, Division of Hematology, Shinshu University School of Medicine, Matsumoto, Japan. 7 Department of Biomedical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto, Japan. 8 Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. satu.mustjoki@helsinki.fi. 9 Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland. satu.mustjoki@helsinki.fi. 10 iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland. satu.mustjoki@helsinki.fi. # Contributed equally.

Repertoire analyses reveal T cell antigen receptor sequence features that influence T cell fate

Lagattuta KA, et al.
Nature Immunology
March 2022
Authors and Affiliates
Kaitlyn A Lagattuta 1,2,3,4,5, Joyce B Kang 1,2,3,4,5, Aparna Nathan 1,2,3,4,5, Kristen E Pauken 6,7, Anna Helena Jonsson 3, Deepak A Rao 3, Arlene H Sharpe 5,6,7, Kazuyoshi Ishigaki #,8,9,10,11, Soumya Raychaudhuri #,12,13,14,15,16,17; 1 Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA. 2 Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 3 Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 4 Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA. 5 Broad Institute of MIT and Harvard, Cambridge, MA, USA. 6 Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. 7 Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA. 8 Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA. kazuyoshi.ishigaki@riken.jp. 9 Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. kazuyoshi.ishigaki@riken.jp. 10 Broad Institute of MIT and Harvard, Cambridge, MA, USA. kazuyoshi.ishigaki@riken.jp. 11 Laboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. kazuyoshi.ishigaki@riken.jp. 12 Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA. soumya@broadinstitute.org. 13 Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. soumya@broadinstitute.org. 14 Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. soumya@broadinstitute.org. 15 Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA. soumya@broadinstitute.org. 16 Broad Institute of MIT and Harvard, Cambridge, MA, USA. soumya@broadinstitute.org. 17 Centre for Genetics and Genomics Versus Arthritis, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. soumya@broadinstitute.org. # Contributed equally.

Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures

Vaca AM, et al.
February 2022
Authors and Affiliates
Alicia M Vaca 1, Nikolaos Ioannou 2, Mariela Sivina 1, Elisavet Vlachonikola 3, Karen Clise-Dwyer 4, Ekaterina Kim 1, Dan Li 4, Qing Ma 4, Alessandra Ferrajoli 1, Zeev Estrov 1, William G Wierda 1, Piers E M Patten 2, Alan G Ramsay 2, Jan A Burger 5; 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2 School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK. 3 Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece. 4 Department of Stem Cell Transplantation and Hematopoietic Biology & Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jaburger@mdanderson.org.

Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes

Shah P, et al.
Journal for ImmunoTherapy of Cancer
February 2022
Authors and Affiliates
Parin Shah #,1, Marie-Andrée Forget #,1,2, Meredith L Frank #,3, Peixin Jiang 3, Donastas Sakellariou-Thompson 2, Lorenzo Federico 1, Roohussaba Khairullah 3, Chantal Alexia Neutzler 2, Ignacio Wistuba 3,4, Chi-Wan B Chow 4, Yan Long 4, Junya Fujimoto 4, Shiaw-Yih Lin 5, Anirban Maitra 4, Marcelo V Negrao 3, Kyle Gregory Mitchell 6, Annikka Weissferdt 7, Ara A Vaporciyan 6, Tina Cascone 3, Jack A Roth 6, Jianjun Zhang 3, Boris Sepesi 6, Don L Gibbons 3, John V Heymach 3, Cara L Haymaker 4, Daniel J McGrail 8, Alexandre Reuben 9, Chantale Bernatchez 10,2; 1 Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 2 Biologics Development, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 3 Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 4 Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 5 Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 6 Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 7 Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 8 Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA cbernatchez@mdanderson.org AReuben@mdanderson.org djmcgrail@mdanderson.org. 9 Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA cbernatchez@mdanderson.org AReuben@mdanderson.org djmcgrail@mdanderson.org. 10 Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA cbernatchez@mdanderson.org AReuben@mdanderson.org djmcgrail@mdanderson.org. # Contributed equally.